GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Apollon Formularies PLC (AQSE:APOL) » Definitions » ROE % Adjusted to Book Value

Apollon Formularies (AQSE:APOL) ROE % Adjusted to Book Value : -102.28% (As of Jun. 2023)


View and export this data going back to . Start your Free Trial

What is Apollon Formularies ROE % Adjusted to Book Value?

Apollon Formularies's ROE % for the quarter that ended in Jun. 2023 was -59.32%. Apollon Formularies's PB Ratio for the quarter that ended in Jun. 2023 was 0.58. Apollon Formularies's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2023 was -102.28%.


Apollon Formularies ROE % Adjusted to Book Value Historical Data

The historical data trend for Apollon Formularies's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollon Formularies ROE % Adjusted to Book Value Chart

Apollon Formularies Annual Data
Trend Jun10 Jun11 Dec12 Dec13 Dec14 Dec17 Dec18 Dec19 Dec20 Dec21
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -1,642.00 -56.18 -30.54 -14.47

Apollon Formularies Semi-Annual Data
Jun11 Jun12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Jun23
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.64 -375.40 -7.55 -3.14 -102.28

Competitive Comparison of Apollon Formularies's ROE % Adjusted to Book Value

For the Drug Manufacturers - Specialty & Generic subindustry, Apollon Formularies's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apollon Formularies's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Apollon Formularies's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Apollon Formularies's ROE % Adjusted to Book Value falls into.



Apollon Formularies ROE % Adjusted to Book Value Calculation

Apollon Formularies's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2021 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-95.91% / 6.63
=-14.47%

Apollon Formularies's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-59.32% / 0.58
=-102.28%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Apollon Formularies ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Apollon Formularies's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Apollon Formularies (AQSE:APOL) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
6 Hope Street, Quayside House, Castletown, IMN, IM9 1AS
Apollon Formularies PLC is a London, England and Jamaican based medical cannabis pharmaceutical company specialising in research and treatment of patients with cancer and chronic pain. It is engaged in investing by seeking to acquire a direct and/or indirect interest in projects and assets in the agriculture and logistics sectors and the medicinal cannabis sector. The company focus on opportunities in Africa and Europe. It has created proprietary hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products.

Apollon Formularies (AQSE:APOL) Headlines

From GuruFocus

FPA Capital Fund 4th Quarter 2015 Commentary

By Holly LaFon Holly LaFon 02-08-2016

Richard Pzena Reduces APOL as Phoenix Rises for Others

By Sally Jones Sally Jones 03-11-2013

7 Arbitrage Trades With High Profit Potential

By Jonathan Poland Jonathan Poland 11-30-2016

Weekly Guru Bargains Highlights: APOL, GNW, BTU, NIHD, OKE

By GuruFocus GuruFocus 06-30-2012

Weekly 3-Year Low Highlights: APOL, PDLI, TC, ALLT, ELRC

By Jimmy Xiao gurujx 05-17-2015

Update from FPA Capital - Seven Changes to Portfolio

By Sally Jones Sally Jones 07-14-2013

FPA Capital Fund Q1 2013 Commentary

By Holly LaFon Holly LaFon 04-24-2013

FPA Capital Fund Finds Only 2 Stocks Matching Their Criteria in Q1

By Holly LaFon Holly LaFon 04-10-2013

6 Highly Predictable Companies with Historically Low P/S Ratios

By Dianne Tordillo Dianne Tordillo 11-27-2012